Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | HPGDS | O60760 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13757164 | 0.88 | ALDH1A1 (0.53) | ALDH1A1PTPN1HPGDSRAB9AGAA | |
| SCHEMBL12894475 | 0.86 | ALDH1A1 (0.51) | ALDH1A1HPGDSRAB9AGAANPC1 | |
| SCHEMBL12925917 | 0.84 | HSD17B1 (0.49) | ALDH1A1PTPN1HPGDSRAB9AGAA | |
| SCHEMBL2638322 | 0.82 | ALDH1A1 (0.55) | ALDH1A1PTPN1HPGDSADRB2ADRB1 | |
| SCHEMBL3412110 | 0.82 | ALDH1A1 (0.71) | ALDH1A1PTPN1HPGDSRAB9AGAA | |
| SCHEMBL10037306 | 0.82 | ALDH1A1 (0.71) | ALDH1A1PTPN1HPGDSRAB9AGAA | |
| SCHEMBL3098211 | 0.82 | ALDH1A1 (1.00) | ALDH1A1PTPN1HPGDSRAB9AGAA | |
| Hydrochloric Acid SCHEMBL6821165 | 0.81 | ALDH1A1 (0.69) | ALDH1A1PTPN1HPGDSRAB9AGAA | |
| Hydrochloric Acid SCHEMBL6822031 | 0.81 | ALDH1A1 (0.97) | ALDH1A1PTPN1HPGDSRAB9AGAA | |
| SCHEMBL29911269 | 0.80 | RAB9A (0.66) | ALDH1A1RAB9AGAANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727797-B1 | PROCESS FOR CROSS COUPLING INDOLES | BOEHRINGER INGELHEIM PHARMA (US) | 2012-05-30 | — | — | EP | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7576079-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-08-18 | — | — | US | disclosed |
| US-20090087409-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-04-02 | — | — | US | disclosed |
| US-20090087409-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-04-02 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-0262873-B1 | N-TETRAZOLYL THIAZOLECARBOXAMIDE DERIVATIVES AND THEIR USE | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1991-08-21 | — | — | EP | disclosed |
| US-4879295-A | ANTIALLERGENS | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1989-11-07 | — | — | US | disclosed |
| EP-0262873-A1 | N-tetrazolyl thiazolecarboxamide derivatives and their use | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1988-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087409-A1 | Viral Polymerase Inhibitors | NR2C2, NR4A1, MED25 | ALDH1A1 3616/4885PTPN1 642/4885HPGDS 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.